Short Interest in Fresenius SE & Co. (OTCMKTS:FSNUY) Expands By 584.4%

Posted by Mitch Edgeman on Jun 27th, 2026

Fresenius SE & Co. (OTCMKTS:FSNUY – Get Free Report) was the recipient of a large growth in short interest in June. As of June 15th, there was short interest totaling 59,293 shares, a growth of 584.4% from the May 31st total of 8,663 shares. Approximately 0.0% of the shares of the stock are sold short. Based on an average daily trading volume, of 412,091 shares, the days-to-cover ratio is presently 0.1 days.

Analysts Set New Price Targets

Separately, Morgan Stanley reiterated an “overweight” rating on shares of Fresenius SE & Co. in a research note on Tuesday. Three research analysts have rated the stock with a Buy rating, According to MarketBeat, the stock has an average rating of “Buy”.

Read Our Latest Analysis on Fresenius SE & Co.

Fresenius SE & Co. Price Performance

OTCMKTS FSNUY traded down $0.06 during trading hours on Friday, hitting $11.41. 132,654 shares of the company’s stock traded hands, compared to its average volume of 191,743. The company has a market capitalization of $25.71 billion, a PE ratio of 15.21 and a beta of 0.64. The company has a debt-to-equity ratio of 0.41, a current ratio of 1.27 and a quick ratio of 0.98. Fresenius SE & Co. has a 52-week low of $10.33 and a 52-week high of $33.93. The firm’s 50-day moving average is $11.51 and its 200-day moving average is $13.16.

Fresenius SE & Co. (OTCMKTS:FSNUY – Get Free Report) last posted its quarterly earnings results on Wednesday, May 6th. The company reported $0.24 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.25 by ($0.01). The company had revenue of $6.75 billion during the quarter, compared to analysts’ expectations of $6.79 billion. Fresenius SE & Co. had a net margin of 6.55% and a return on equity of 10.09%. Equities analysts forecast that Fresenius SE & Co. will post 1.03 EPS for the current fiscal year.

About Fresenius SE & Co.

(Get Free Report)

Fresenius SE & Co KGaA is a global healthcare group headquartered in Bad Homburg vor der Höhe, Germany. Founded in 1912 by Eduard Fresenius, the company has grown into one of the world’s leading providers of products and services for dialysis, hospitals and outpatient medical care. Trading on major European exchanges and available over the counter in the U.S. as FSNUY, Fresenius SE & Co brings together a portfolio of specialized healthcare businesses under one corporate umbrella.

The company operates through four main business segments.